Insys stock: buy or sell?
June 28th, 2019
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.
Should I buy Insys stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Insys stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Insys stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we collected 2 ratings published for INSY stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-3-8||Royal Bank of Canada||Outperform||Outperform|
Insys stock analysis
After sliding for 4 days, June 28th Insys Therapeutics rocketed an extraordinary 25,307,307,592.31%, closing at $65,799,000.00.
Insys shares broke up the simple moving average line of 200 days today and closed at $65,799,000.00. On June 28th, SMA100d and SMA200d crossed up triggering a rise of 25,307,307,592.31%. INSY broke out again over $0.74 after a 72.97% correction started on Jun 12th.
After sliding a chilling -30.77% in a week by mid June, Insys closed this week at $65,799,000.00 and rocketed a super good 25,307,307,592.31%.
Late June, SMA20w and SMA40w crossed up triggering a rise of 25,307,307,592.31%. Since price and SMA40w lines crossed up late June, INSY climbed $65,798,999.74 (25,307,307,592.31%).
Insys stock price history
Insys IPO was on November 2nd, 2017 at $4.79 per share1. Since then, INSY stock grew a 1,373,674,221.50%, with an average of 1,373,674,221.50% per year. If you had invested right after INSY's IPO a $1,000 in Insys stock in 2017, it would worth $13,736,742,215.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Insys stock historical price chart
INSY stock reached 52-week highs on August at $11.65, and all-time highs 2018-01-03 with a price of 14.
Insys stock price target is $7.00Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' INSY stock price predictions in the hope that they will be met as they may be wrong and not met. Currently, only 1 price prediction for Insys Therapeutics stock was posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-8||Royal Bank of Canada||Lowers Target||$9.00||$7.00||-22.2%|
Financials and fundamental analysis
Earnings date and Earnings per ShareInsys presented cool results for 2018-Q4 on March. Insys Therapeutics soared Earnings per Share (EPS) by 18.20%, beating experts of $-0.33. Insys Therapeutics posted $-0.39.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Insys annual revenues plummed a scary -41.66% to $82.08 M USD from $140.69 marked in 2017. When comparing 2018 vs 2017, by contrast, profit margin (that is, the net income divided by revenues) jumped a 9.54% to -151.69%.
|2013||$99 M||-||$40 M40.7%||-|
|2014||$222 M||123.71%||$38 M17.1%||-5.95%|
|2015||$331 M||48.92%||$58 M17.7%||53.98%|
|2016||$242 M||-26.76%||$7.59 M3.1%||-87.02%|
|2017||$141 M||-41.93%||$-226.84 M-161.2%||-3,088.60%|
|2018||$82 M||-41.66%||$-124.51 M-151.7%||-45.11%|
Quarterly financial resultsInsys reported $16.36 million in revenues for 2018-Q4, a -10.84% decline compared to previous quarter. Reported quarter income marked $-46.29 million with a profit margin of -283.02%. Profit margin plunged a -116.80% compared to previous quarter when profit margin was -166.22%. When comparing sales to same quarter last year, Insys Therapeutics sales marked a frightening correction and plummed a -48.05%. Looking back to recent quarterly results, Insys posted 4 positive quarters in a row.
|2017-Q1||$36 M||-||$-6.52 M-18.1%||-|
|2017-Q2||$43 M||18.41%||$-8.18 M-19.2%||25.46%|
|2017-Q3||$31 M||-27.97%||$-166.32 M-542.3%||1,933.25%|
|2017-Q4||$31 M||2.66%||$-47.11 M-149.6%||-71.68%|
|2018-Q1||$24 M||-24.06%||$-20.37 M-85.2%||-56.76%|
|2018-Q2||$23 M||-1.86%||$-27.35 M-116.6%||34.27%|
|2018-Q3||$18 M||-21.82%||$-30.49 M-166.2%||11.50%|
|2018-Q4||$16 M||-10.84%||$-46.29 M-283.0%||51.81%|
Insys ownershipWhen you are planning to buy shares of a company, it's always worth to check its ownership structure.
Insys Therapeutics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
The following table compares ownership indicators for other stocks related to Insys Therapeutics:
|Market cap||$0.0 M||$218.6 M||$218.5 M||$5.2 B||$1.4 B|
|Total shares||0.0 M||78.9 M||55.9 M||30.7 M||79.2 M|
|Float shares||0.0 M||77.9 M||71.8 M||29.8 M||66.0 M|
|- Institutional holdings (%)||0.0%||19.7%||58.8%||82.0%||117.6%|
|- Insider holdings (%)||0.0%||11.6%||6.0%||0.6%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, June 28th, 2019|
|Day range||$0.25 - $0.38|
|Average true range||$0.31|
|50d mov avg||$1,315,980.00|
|100d mov avg||$657,994.00|
|200d mov avg||$329,000.00|
Insys performanceTo better understand Insys performance you must compare its gains with other related stocks in same sector or industry. We compared Insys against AcelRx Pharmaceuticals, BioDelivery Sciences International, GW Pharmaceuticals, Heron Therapeutics, Merck, Mylan and Recro Pharma in the following table: